Collection activity

Recently added peptide evidence

Discover the latest 100 records added to PeptideScanner across 3 evidence lanes. “Added” is the site publication date; each card separately shows the date carried by the cited source.

100Latest additions
3Evidence lanes
November 17, 2026Most recent addition
27Connected peptides

Literature metadata · Added to PeptideScanner

Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.↗

PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 17, 2026 · Attributed publication date January 2027 (month precision) · Degarelix

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05344469↗

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Registry update November 16, 2026 · Glatiramer acetate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07715903↗

PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Registry update November 16, 2026 · Carfilzomib

→

Literature metadata · Added to PeptideScanner

Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.↗

PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 14, 2026 · Attributed publication date November 9, 2026 (day precision) · Cerebrolysin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT03606577↗

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Registry update November 12, 2026 · Carfilzomib

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT06152575↗

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Registry update November 12, 2026 · Carfilzomib

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07555938↗

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Registry update November 10, 2026 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Federal Register notice 2026-15149↗

The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

Regulatory record date July 28, 2026 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA209526↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date July 20, 2026 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA219604↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date June 4, 2026 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA220934↗

The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.↗

Regulatory record date April 1, 2026 · Orforglipron

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA218602↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date February 26, 2026 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA213382↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date February 11, 2026 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA214022↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date February 11, 2026 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA214741↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date December 31, 2025 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA218929↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date November 26, 2025 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA217591↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date November 10, 2025 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA219465↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date October 23, 2025 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA208468↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date May 7, 2025 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA203857↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date September 25, 2024 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA206873↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date September 25, 2024 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA209330↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date June 11, 2021 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA211185↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date March 20, 2020 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA209425↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date March 16, 2020 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA209422↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date September 9, 2019 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Federal Register notice 2019-09007↗

The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

Regulatory record date May 3, 2019 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Federal Register notice 2019-02146↗

The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.↗

Regulatory record date February 13, 2019 · Peginesatide

→

Regulatory · Added to PeptideScanner

Federal Register notice 2018-15735↗

The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

Regulatory record date July 23, 2018 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA206921↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date February 12, 2018 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Federal Register notice 2018-02768↗

The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

Regulatory record date February 12, 2018 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA091646↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date October 3, 2017 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA206936↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date October 3, 2017 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Federal Register notice 2016-22935↗

The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗

Regulatory record date September 23, 2016 · Metreleptin

→

Regulatory · Added to PeptideScanner

Federal Register notice 2016-13797↗

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.↗

Regulatory record date June 10, 2016 · Albiglutide

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA208547↗

The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.↗

Regulatory record date June 1, 2016 · Gallium Ga 68 dotatate

→

Regulatory · Added to PeptideScanner

Federal Register notice 2016-08682↗

The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

Regulatory record date April 15, 2016 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Federal Register proposed rule 2015-32246↗

The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

Regulatory record date December 23, 2015 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application ANDA090218↗

The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date April 16, 2015 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA021883↗

The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Regulatory record date May 23, 2014 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Federal Register notice 2014-11523↗

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.↗

Regulatory record date May 20, 2014 · Peginesatide

→

Regulatory · Added to PeptideScanner

Federal Register notice 2014-11175↗

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.↗

Regulatory record date May 15, 2014 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application BLA125431↗

The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.↗

Regulatory record date April 15, 2014 · Albiglutide

→

Regulatory · Added to PeptideScanner

Drugs@FDA application BLA125390↗

The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.↗

Regulatory record date February 24, 2014 · Metreleptin

→

Regulatory · Added to PeptideScanner

Federal Register notice 2014-02942↗

The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

Regulatory record date February 12, 2014 · Dalbavancin

→

Regulatory · Added to PeptideScanner

Federal Register notice 2013-25588↗

The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗

Regulatory record date October 30, 2013 · Metreleptin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA202714↗

The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.↗

Regulatory record date July 20, 2012 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Federal Register notice 2012-10154↗

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.↗

Regulatory record date April 27, 2012 · Carfilzomib

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA202799↗

The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.↗

Regulatory record date March 27, 2012 · Peginesatide

→

Regulatory · Added to PeptideScanner

Federal Register notice 2011-27327↗

The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.↗

Regulatory record date October 24, 2011 · Peginesatide

→

Regulatory · Added to PeptideScanner

Federal Register notice E6-12571↗

The Federal Register published notice E6-12571, attributed to FDA and its parent HHS department, on 2006-08-03. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Regulatory record date August 3, 2006 · Mecasermin

→

Regulatory · Added to PeptideScanner

Federal Register notice E6-9138↗

The Federal Register published notice E6-9138, attributed to FDA and its parent HHS department, on 2006-06-13. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Regulatory record date June 13, 2006 · Mecasermin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application BLA021839↗

The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.↗

Regulatory record date August 30, 2005 · Mecasermin

→

Regulatory · Added to PeptideScanner

Federal Register notice 98-7053↗

The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Regulatory record date March 19, 1998 · Mecasermin

→

Regulatory · Added to PeptideScanner

Federal Register notice 97-10541↗

The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Regulatory record date April 23, 1997 · Mecasermin

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA020622↗

The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.↗

Regulatory record date December 20, 1996 · Glatiramer acetate

→

Regulatory · Added to PeptideScanner

Drugs@FDA application NDA018123↗

The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record's active ingredients.↗

Regulatory record date September 30, 1982 · Gonadorelin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05278208↗

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 16, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT06285396↗

PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin.↗

Registry update November 16, 2026 · Oxytocin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07868835↗

PeptideScanner retained ClinicalTrials.gov record NCT07868835 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was vk2735.↗

Registry update November 16, 2026 · VK2735

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07940244↗

PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.↗

Registry update November 16, 2026 · Survodutide

→

Literature metadata · Added to PeptideScanner

Tirzepatide in Adolescents With Obesity: Research Summary.↗

PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 15, 2026 · Attributed publication date November 15, 2026 (day precision) · Tirzepatide

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT04234568↗

PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 13, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT06930391↗

PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin.↗

Registry update November 13, 2026 · Oxytocin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07935304↗

PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide.↗

Registry update November 13, 2026 · Eloralintide

→

Literature metadata · Added to PeptideScanner

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.↗

PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 13, 2026 · Attributed publication date May 21, 2025 (day precision) · Carfilzomib

→

Literature metadata · Added to PeptideScanner

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.↗

PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 13, 2026 · Attributed publication date November 13, 2026 (day precision) · Pegcetacoplan

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT04665739↗

PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 12, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT04750954↗

PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 12, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05178693↗

PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 12, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05691465↗

PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 12, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05773274↗

PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 12, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT06722157↗

PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

Registry update November 12, 2026 · Pegcetacoplan

→

Literature metadata · Added to PeptideScanner

Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area.↗

PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 12, 2026 · Attributed publication date May 25, 2026 (day precision) · Oxytocin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT03531255↗

PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

Registry update November 10, 2026 · Pegcetacoplan

→

Literature metadata · Added to PeptideScanner

Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine.↗

PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 10, 2026 · Attributed publication date November 7, 2026 (day precision) · Pegcetacoplan

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT02262806↗

PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Registry update November 9, 2026 · Metreleptin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05164341↗

PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Registry update November 9, 2026 · Metreleptin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT06955169↗

PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

Registry update November 9, 2026 · Lutetium Lu 177 dotatate

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07898774↗

PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

Registry update November 9, 2026 · Pegcetacoplan

→

Literature metadata · Added to PeptideScanner

Producing human mechano growth factor (MGF) in Escherichia coli.↗

PubMed lists PMID 18068377 in Protein expression and purification as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-07 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date November 7, 2007 (day precision) · PEG-MGF

→

Literature metadata · Added to PeptideScanner

Peginesatide acetate, axitinib, and pertuzumab.↗

PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date 2012 Sep-Oct (source-text precision) · Peginesatide

→

Literature metadata · Added to PeptideScanner

An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.↗

PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date September 1989 (month precision) · Nafarelin

→

Literature metadata · Added to PeptideScanner

Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.↗

PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date April 27, 2021 (day precision) · Dasiglucagon

→

Literature metadata · Added to PeptideScanner

Dasiglucagon Hydrochloride.↗

PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date July 22, 2021 (day precision) · Dasiglucagon

→

Literature metadata · Added to PeptideScanner

Metreleptin treatment of non-HIV lipodystrophy syndromes.↗

PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date September 24, 2021 (day precision) · Metreleptin

→

Literature metadata · Added to PeptideScanner

Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.↗

PubMed lists PMID 35436057 in The Egyptian journal of immunology as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date April 2022 (month precision) · Thymosin beta-4

→

Literature metadata · Added to PeptideScanner

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…↗

PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date December 15, 2022 (day precision) · Carfilzomib

→

Literature metadata · Added to PeptideScanner

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.↗

PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date April 17, 2023 (day precision) · Motixafortide

→

Literature metadata · Added to PeptideScanner

Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case.↗

PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date May 15, 2023 (day precision) · Lutetium Lu 177 dotatate

→

Literature metadata · Added to PeptideScanner

177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.↗

PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date October 23, 2023 (day precision) · Lutetium Lu 177 dotatate

→

Literature metadata · Added to PeptideScanner

Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: serum and skeletal muscle profile.↗

PubMed lists PMID 41186863 in Journal of endocrinological investigation as Journal Article, with publication-date metadata of 2025-11-04 (day precision). PeptideScanner associated the retained record with the identity slug humanin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date November 4, 2025 (day precision) · Humanin

→

Literature metadata · Added to PeptideScanner

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.↗

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date April 17, 2026 (day precision) · Orforglipron

→

Literature metadata · Added to PeptideScanner

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.↗

PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date August 21, 2026 (day precision) · Motixafortide

→

Literature metadata · Added to PeptideScanner

Orforglipron for Obstructive Sleep Apnea: Research Summary.↗

PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date November 9, 2026 (day precision) · Orforglipron

→

Literature metadata · Added to PeptideScanner

Efinopegdutide: a step towards precision in MASH therapy?↗

PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 9, 2026 · Attributed publication date November 9, 2026 (day precision) · Efinopegdutide

→

Literature metadata · Added to PeptideScanner

Nesiritide in acute decompensated heart failure: current status and future perspectives.↗

PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 8, 2026 · Attributed publication date 2008 Summer (source-text precision) · Nesiritide

→

Literature metadata · Added to PeptideScanner

Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence.↗

PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 8, 2026 · Attributed publication date May 16, 2026 (day precision) · Oxytocin

→

Literature metadata · Added to PeptideScanner

Beyond lactation: Central oxytocin in maternal mental health and disease.↗

PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

PubMed metadata revision November 6, 2026 · Attributed publication date April 17, 2026 (day precision) · Oxytocin

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT05555589↗

PeptideScanner retained ClinicalTrials.gov record NCT05555589 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗

Registry update November 5, 2026 · Thymosin beta-4

→

Clinical trials · Added to PeptideScanner

ClinicalTrials.gov record NCT07794579↗

PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.↗

Registry update November 5, 2026 · Orforglipron

→